LUCY ANN GODLEY

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
    Qiwei Yang
    Department of Pediatrics, University of Chicago, 900 Ease 57th Street, KCBD Rm, 5100 Chicago, IL 60637, USA
    BMC Cancer 10:286. 2010
  2. ncbi HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor?
    Lucy A Godley
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 48:1898-9. 2007
  3. ncbi Therapy-related myeloid leukemia
    Lucy A Godley
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 35:418-29. 2008
  4. ncbi Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant
    Lucy A Godley
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 51:995-1006. 2010
  5. ncbi Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia
    Zhijian Qian
    Section of Hematology Oncology and the Cancer Research Center, University of Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 99:14925-30. 2002
  6. ncbi Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1809-17. 2009
  7. ncbi Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew S Artz
    Section of Hematology Oncology, Department of Medicine, University of Chicago, the University of Chicago Cancer Research Center, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:1209-16. 2008
  8. ncbi The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells
    Ozden Ozer
    Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 49:1567-77. 2008
  9. ncbi DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis
    Mrinal Y Shah
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637 1470, USA
    Cancer Res 70:5840-50. 2010
  10. ncbi The use of hypomethylating agents in the treatment of hematologic malignancies
    Jane E Kihslinger
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 48:1676-95. 2007

Research Grants

  1. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    Lucy Godley; Fiscal Year: 2009
  2. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    LUCY ANN GODLEY; Fiscal Year: 2010
  3. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    LUCY ANN GODLEY; Fiscal Year: 2010

Collaborators

Detail Information

Publications10

  1. ncbi Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
    Qiwei Yang
    Department of Pediatrics, University of Chicago, 900 Ease 57th Street, KCBD Rm, 5100 Chicago, IL 60637, USA
    BMC Cancer 10:286. 2010
    ....
  2. ncbi HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor?
    Lucy A Godley
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 48:1898-9. 2007
  3. ncbi Therapy-related myeloid leukemia
    Lucy A Godley
    Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 35:418-29. 2008
    ..Ultimately, this knowledge could influence initial treatment strategies with the goal of decreasing the incidence of this serious complication...
  4. ncbi Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant
    Lucy A Godley
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 51:995-1006. 2010
    ..The remission induction of high-dose cytarabine and mitoxantrone for t-MN is a well-tolerated efficacious combination, which allows aggressive consolidation and long-term disease-free survival...
  5. ncbi Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia
    Zhijian Qian
    Section of Hematology Oncology and the Cancer Research Center, University of Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 99:14925-30. 2002
    ..Establishing the molecular pathways involved in t-AML may facilitate the identification of selectively expressed genes that can be exploited for the development of urgently needed targeted therapies...
  6. ncbi Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1809-17. 2009
    ..The high incidence of MDC after alemtuzumab containing conditioning contributes to the low risk of acute and chronic GVHD...
  7. ncbi Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew S Artz
    Section of Hematology Oncology, Department of Medicine, University of Chicago, the University of Chicago Cancer Research Center, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:1209-16. 2008
    ..These data require confirmation in non-T cell-depleted conditioning regimens. If validated, they suggest that preconditioning CRP holds promise for enhancing estimates of transplantation tolerance...
  8. ncbi The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells
    Ozden Ozer
    Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 49:1567-77. 2008
    ..Our discovery of novel KIT transcripts underscores the importance of analysing entire protein encoding regions when studying genes of interest...
  9. ncbi DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis
    Mrinal Y Shah
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637 1470, USA
    Cancer Res 70:5840-50. 2010
    ..These data represent the first in vivo modeling of cancer-associated DNA methylation changes and suggest that truncated DNMT3B isoforms contribute to the redistribution of DNA methylation characterizing virtually every human tumor...
  10. ncbi The use of hypomethylating agents in the treatment of hematologic malignancies
    Jane E Kihslinger
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 48:1676-95. 2007
    ..Future studies are likely to combine these agents with other drugs like the histone deacetylase inhibitors that act in related pathways...

Research Grants4

  1. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    Lucy Godley; Fiscal Year: 2009
    ....
  2. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    LUCY ANN GODLEY; Fiscal Year: 2010
    ....
  3. The Role of DNMT3B in the DNA Methylation of Cancer Cells
    LUCY ANN GODLEY; Fiscal Year: 2010
    ....